Search

CytomX Therapeutics Inc

Suletud

SektorTervishoid

2.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.66

Max

3.19

Põhinäitajad

By Trading Economics

Sissetulek

-2.4M

-21M

Müük

-8.8M

1.4M

P/E

Sektori keskmine

22.5

56.432

Aktsiakasum

-0.09

Kasumimarginaal

-1,457.405

Töötajad

69

EBITDA

-2.4M

-20M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+314.06% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

7.2M

697M

Eelmine avamishind

2.82

Eelmine sulgemishind

2.82

Uudiste sentiment

By Acuity

50%

50%

129 / 339 Pingereas Healthcare

CytomX Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. sept 2026, 23:51 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. This marks a shift from recent trends.

14. sept 2026, 20:07 UTC

CytomX Therapeutics Inc shares are lower amid broader market weakness and rising crude oil prices, with no specific news identified to explain the decline.

11. sept 2026, 20:08 UTC

CytomX Therapeutics Inc's shares are lower today, continuing a trend of four consecutive sessions with declines and trading below the 20-day moving average.

10. sept 2026, 20:07 UTC

CytomX Therapeutics Inc shares declined during Thursday's session, continuing a downward trend with no specific news identified to explain the movement.

9. sept 2026, 19:26 UTC

CytomX Therapeutics shares are lower during Wednesday's session, continuing a decline since Tuesday's close, amid broader market reactions to rising crude oil prices.

8. sept 2026, 23:01 UTC

CytomX Therapeutics Inc shares are higher in after-market trading, maintaining a strong position above its 20-day moving average amid broader market trends.

4. sept 2026, 20:07 UTC

CytomX Therapeutics Inc shares are higher during Friday's session, recovering from an earlier dip and remaining above the 20-day moving average.

2. sept 2026, 20:08 UTC

Social Media

CytomX Therapeutics shares are higher, supported by Piper Sandler's $12 price target and positive sentiment in the Biotechnology sector ahead of upcoming data releases.

1. sept 2026, 20:01 UTC

Social Media
News

CytomX Therapeutics is trading higher as it announces participation in key investor conferences and growing fund interest ahead of upcoming data releases.

31. aug 2026, 20:07 UTC

CytomX Therapeutics is trading higher, following broader market gains since Friday. No specific company news was identified to explain the increase.

28. aug 2026, 19:51 UTC

Event

CytomX Therapeutics shares are lower despite FDA granting Fast Track Designation for Varseta-M to treat metastatic colorectal cancer. Trading volume is unusually high.

27. aug 2026, 23:02 UTC

Event

CytomX Therapeutics received Fast Track Designation for Varseta-M, yet shares are trading lower in after-market hours, breaking a recent trend of gains.

25. aug 2026, 19:56 UTC

CytomX Therapeutics is trading higher amid positive market conditions and lower crude oil prices, which have decreased treasury yields and boosted investor sentiment.

24. aug 2026, 19:26 UTC

CytomX Therapeutics is trading higher, reflecting gains since Friday's close. Earlier, shares peaked with a gain before pulling back to a modest advance.

21. aug 2026, 19:46 UTC

CytomX Therapeutics Inc. is gaining during Friday's session, despite earlier volatility. No specific company news was identified to explain today's price movement.

20. aug 2026, 21:01 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, reflecting unusual trading activity. The stock is positioned around the midpoint of its one-month range.

19. aug 2026, 20:02 UTC

CytomX Therapeutics is trading higher during Wednesday's session, continuing a strong upward move since Tuesday's close amid notable volatility.

14. aug 2026, 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

13. aug 2026, 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

12. aug 2026, 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

11. aug 2026, 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

10. aug 2026, 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

7. aug 2026, 19:16 UTC

Social Media
News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

6. aug 2026, 22:02 UTC

Social Media
News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

31. juuli 2026, 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

29. juuli 2026, 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

28. juuli 2026, 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

27. juuli 2026, 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

21. juuli 2026, 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

CytomX Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

314.06% tõus

12 kuu keskmine prognoos

Keskmine 13.25 USD  314.06%

Kõrge 16 USD

Madal 11 USD

Põhineb 4 Wall Streeti analüütiku instrumendi CytomX Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

4

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

129 / 339 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
help-icon Live chat